CME/CE - PACE-CME

Episodes 65-80 of 115

Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
MinuteCE®
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
0.75 program credits
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 program credits
MinuteCE®
Clinical choices in managing LDL-c: Where do novel therapies fit in?
0.75 credits 4 episodes
- Kausik Ray, MBChB, MD, MPhil
- Julia Brandts, MD
- Pasquale Perrone-Filardi, MD, PhD
- Ulrich Laufs, MD, PhD
0.75 credits 4 episodes
MinuteCE®
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
0.75 credits 3 episodes
- Gianluigi Savarese, MD
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 credits 3 episodes
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Scott Solomon, MD
- Mikhail Kosiborod, MD
0.50 credits
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Managing a patient with residual risk: Applying recent evidence with EPA to practice
MinuteCE®
Managing a patient with residual risk: Applying recent evidence with EPA to practice
0.50 program credits
- Prof. Kausik Ray
0.50 program credits
MinuteCE®
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
0.50 credits 3 episodes
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Erin Michos
0.50 credits 3 episodes
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
MinuteCE®
Integrating EPA in CV risk reduction strategies: Practical experience and guidance
0.50 program credits
- Azfar Zaman, MD
0.50 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
MinuteCE®
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
0.50 program credits
- Erin Michos
0.50 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 program credits
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
0.50 program credits
CETP inhibition: Lessons from two decades of clinical trials
CETP inhibition: Lessons from two decades of clinical trials
MinuteCE®
CETP inhibition: Lessons from two decades of clinical trials
0.50 program credits
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
0.50 program credits
Understanding the etiology of HCM and pathways for intervention
Understanding the etiology of HCM and pathways for intervention
MinuteCE®
Understanding the etiology of HCM and pathways for intervention
0.75 program credits
- Roberto Barriales-Villa, MD, PhD
0.75 program credits
What are the challenges in making the right diagnosis in HCM?
What are the challenges in making the right diagnosis in HCM?
MinuteCE®
What are the challenges in making the right diagnosis in HCM?
0.75 program credits
- Perry Elliott, MD
0.75 program credits

5/8